Xencor, Inc.
HETERODIMERIC ANTIBODIES THAT BIND MSLN AND CD3
Last updated:
Abstract:
The present invention is directed to antibodies, including novel antigen binding domains and heterodimeric antibodies, that bind Mesothelin (MSLN).
Status:
Application
Type:
Utility
Filling date:
14 May 2021
Issue date:
7 Apr 2022